Survival of hepatitis C virus in syringes: Implication for transmission among injection drug users

Journal of Infectious Diseases

Volumn 202, Issue 7, 2010, Pages 984-990

  Paintsil, Elijah ^a   He, Huijie ^a   Peters, Christopher ^a   Lindenbach, Brett D ^a   Heimer, Robert ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LUCIFERASE;

ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; INSULIN SYRINGE; INTRAVENOUS DRUG ABUSE; MICROCULTURE; NONHUMAN; PRIORITY JOURNAL; REPORTER GENE; SEROPREVALENCE; STORAGE TEMPERATURE; SYRINGE; TUBERCULIN SYRINGE; VIRUS CULTURE; VIRUS INFECTIVITY; VIRUS SURVIVAL; VIRUS TRANSMISSION; VIRUS VIABILITY; DISEASE TRANSMISSION; ISOLATION AND PURIFICATION; MICROBIAL VIABILITY; SUBSTANCE ABUSE; VIROLOGY;

HEPACIVIRUS; HEPATITIS C; HUMANS; MICROBIAL VIABILITY; SUBSTANCE ABUSE, INTRAVENOUS; SYRINGES;

EID: 77956930839     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/656212     Document Type: Article

References (48)

1. Cohen J. The scientific challenge of hepatitis C. Science 1999; 285:26-30.
2. Shustov AV, Kochneva GV, Sivolobova GF, et al. Molecular epidemiology of the hepatitis C virus in Western Siberia. J Med Virol 2005; 77:382-389.
3. Ruzibakiev R, Kato H, Ueda R, et al. Risk factors and seroprevalence of hepatitis B virus, hepatitis C virus, and human immunodeficiency virus infection in uzbekistan. Intervirology 2001; 44:327-332.
4. Paintsil E, Verevochkin SV, Dukhovlinova E, et al. Hepatitis C virus infection among drug injectors in St Petersburg, Russia: social and molecular epidemiology of an endemic infection. Addiction 2009; 104:1881-1890.
5. Onishchenko GG, Shakhgil'dian IV. The current problems in the epidemiology and prevention of viral hepatitis B and C in the Russian Federation. Zh Mikrobiol Epidemiol Immunobiol 2000; 1:50-54.
6. MacDonald MA, Wodak AD, Dolan KA, van Beek I, Cunningham PH, Kaldor JM. Hepatitis C virus antibody prevalence among injecting drug users at selected needle and syringe programs in Australia, 1995-1997: collaboration of Australian NSPs. Med J Aust 2000; 172:57-61.
7. Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med 2001; 345:41-52.
8. Hope VD, Judd A, Hickman M, et al. Prevalence of hepatitis C among injection drug users in England and Wales: is harm reduction working? Am J Public Health 2001; 91:38-42.
9. Hagan H, Thiede H, Weiss NS, Hopkins SG, Duchin JS, Alexander ER. Sharing of drug preparation equipment as a risk factor for hepatitis C. Am J Public Health 2001; 91:42-46. (Pubitemid 32049265)
10. Freeman AJ, Zekry A, Whybin LR, et al. Hepatitis C prevalence among Australian injecting drug users in the 1970s and profiles of virus genotypes in the 1970s and 1990s. Med J Aust 2000; 172:588-591.
11. Alter MJ. Prevention of spread of hepatitis C. Hepatology 2002; 36:S93-S98.
12. Chaisson RE, Bacchetti P, Osmond D, Brodie B, Sande MA, Moss AR. Cocaine use and HIV infection in intravenous drug users in San Francisco. JAMA 1989; 261:561-565.
13. Thorpe LE, Ouellet LJ, Hershow R, et al. Risk of hepatitis C virus infection among young adult injection drug users who share injection equipment. Am J Epidemiol 2002; 155:645-653.
14. Koester S, Glanz J, Baron A. Drug sharing among heroin networks: implications for HIV and hepatitis B and C prevention. AIDS Behav 2005; 9:27-39. (Pubitemid 40562182)
15. Tseng FC, O'Brien TR, Zhang M, et al. Seroprevalence of hepatitis C virus and hepatitis B virus among San Francisco injection drug users, 1998 to 2000. Hepatology 2007; 46:666-671.
16. Bluthenthal RN, Do DP, Finch B, Martinez A, Edlin BR, Kral AH. Community characteristics associated with HIV risk among injection drug users in the San Francisco Bay Area: a multilevel analysis. J Urban Health 2007; 84:653-666.
17. Burt RD, Hagan H, Garfein RS, Sabin K, Weinbaum C, Thiede H. Trends in hepatitis B virus, hepatitis C virus, and human immunodeficiency virus prevalence, risk behaviors, and preventive measures among Seattle injection drug users aged 18-30 years, 1994-2004. J Urban Health 2007; 84:436-454.
18. Zeldis JB, Jain S, Kuramoto IK, et al. Seroepidemiology of viral infections among intravenous drug users in northern California. West J Med 1992; 156:30-35.
19. Short LJ, Bell DM. Risk of occupational infection with blood-borne pathogens in operating and delivery room settings. Am J Infect Control 1993; 21:343-350.
20. Gerberding JL. Management of occupational exposures to blood-borne viruses. N Engl J Med 1995; 332:444-451.
21. Cavalcante NJ, Abreu ES, Fernandes ME, et al. Risk of health care professionals acquiring HIV infection in Latin America. AIDS Care 1991; 3:311-316.
22. Gerberding JL. Incidence and prevalence of human immunodeficiency virus, hepatitis B virus, hepatitis C virus, and cytomegalovirus among health care personnel at risk for blood exposure: final report from a longitudinal study. J Infect Dis 1994; 170:1410-1417. (Pubitemid 24369899)
23. Heimer R. Syringe exchange programs: lowering the transmission of syringe-borne diseases and beyond. Public Health Rep 1998; 113(Suppl 1):67-74.
24. Hurley SF, Jolley DJ, Kaldor JM. Effectiveness of needle-exchange programmes for prevention of HIV infection. Lancet 1997; 349:1797-1800.
25. Lurie P, Drucker E. An opportunity lost: HIV infections associated with lack of a national needle-exchange programme in the USA. Lancet 1997; 349:604-608. (Pubitemid 27101887)
26. Kaplan EH, Heimer R. A circulation theory of needle exchange. AIDS 1994; 8:567-574.
27. Kamili S, Krawczynski K, McCaustland K, Li X, Alter MJ. Infectivity of hepatitis C virus in plasma after drying and storing at room temperature. Infect Control Hosp Epidemiol 2007; 28:519-524.
28. Jones CT, Murray CL, Eastman DK, Tassello J, Rice CM. Hepatitis C virus p7 and NS2 proteins are essential for production of infectious virus. J Virol 2007; 81:8374-8383.
29. Phan T, Beran RK, Peters C, Lorenz IC, Lindenbach BD. Hepatitis C virus NS2 protein contributes to virus particle assembly via opposing epistatic interactions with the E1-E2 glycoprotein and NS3-NS4A enzyme complexes. J Virol 2009; 83:8379-8395.
30. Lindenbach BD, Meuleman P, Ploss A, et al. Cell culture-grown hepatitis C virus is infectious in vivo and can be recultured in vitro. Proc Natl Acad Sci U S A 2006; 103:3805-3809.
31. Lindenbach BD, Evans MJ, Syder AJ, et al. Complete replication of hepatitis C virus in cell culture. Science 2005; 309:623-626.
32. Reed LJ, Muench H. A simple method of estimating fifty percent end points. Am J Hyg 1938; 27:493-497.
33. Blight KJ, McKeating JA, Rice CM. Highly permissive cell lines for subgenomic and genomic hepatitis C virus RNA replication. J Virol 2002; 76:13001-13014.
34. Strauss K, van Zundert A, Frid A, Costigliola V. Pandemic influenza preparedness: the critical role of the syringe. Vaccine 2006; 24:4874-4882. (Pubitemid 44218847)
35. Zule WA, Ticknor-Stellato KM, Desmond DP, Vogtsberger KN. Evaluation of needle and syringe combinations. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 14:294-295.
36. Abdala N, Stephens PC, Griffith BP, Heimer R. Survival of HIV-1 in syringes. J Acquir Immune Defic Syndr Hum Retrovirol 1999; 20:73-80.
37. Gaughwin MD, Gowans E, Ali R, Burrell C. Bloody needles: the volumes of blood transferred in simulations of needlestick injuries and shared use of syringes for injection of intravenous drugs. Aids 1991; 5:1025-1027.
38. Grund JP, Stern LS. Residual blood in syringes: size and type of syringe are important. AIDS 1991; 5:1532-1533.
39. Kaplan EH. A method for evaluating needle exchange programmes. Stat Med 1994; 13:2179-187.
40. Zule WA, Desmond DP, Neff JA. Syringe type and drug injector risk for HIV infection: a case study in Texas. Soc Sci Med 2002; 55:1103-1113.
41. Zule WA, Bobashev G. High dead-space syringes and the risk of HIV and HCV infection among injecting drug users. Drug Alcohol Depend 2009; 100:204-213.
42. Cardo DM, Culver DH, Ciesielski CA, et al. A case-control study of HIV seroconversion in health care workers after percutaneous exposure. Centers for Disease Control and Prevention Needlestick Surveillance Group. N Engl J Med 1997; 337:1485-1490.
43. Hallett TB, Singh K, Smith JA, White RG, Abu-Raddad LJ, Garnett GP. Understanding the impact of male circumcision interventions on the spread of HIV in southern Africa. PLoS One 2008; 3:e2212.
44. Cohen MS, Hellmann N, Levy JA, DeCock K, Lange J. The spread, treatment, and prevention of HIV-1: evolution of a global pandemic. J Clin Invest 2008; 118:1244-1254.
45. World Health Organization. Guide to starting and managing needle syringe programmes. http://who.int/hiv/idu/Guide-to-Starting-and-Managing-NSP.pdf. Published 14 March 2007. Accessed 1 January 2010.
46. Farquhar MJ, Harris HJ, Diskar M, et al. Protein kinase A-dependent step(s) in hepatitis C virus entry and infectivity. J Virol 2008; 82:8797-8811.
47. Damen M, Sillekens P, Sjerps M, et al. Stability of hepatitis C virus RNA during specimen handling and storage prior to NASBA amplification. J Virol Methods 1998; 72:175-184.
48. Abdala N, Grund JP, Tolstov Y, Kozlov AP, Heimer R. Can home-made injectable opiates contribute to the HIV epidemic among injection drug users in the countries of the former Soviet Union? Addiction 2006; 101:731-737.